Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass grafts.
Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass grafts.
复制标题
依诺昔酮、多巴酚丁胺及其组合对人动脉冠状动脉搭桥术的血管舒张作用。
DOI：
10.1097/00005344-199911000-00017
复制
发表时间：
1999
影响因子：
3
通讯作者：
P. Devillier
中科院分区：
文献类型：
--
作者：
J. Cracowski;F. Stanke;O. Chavanon;D. Blin;J. Mallion;G. Bessard;P. Devillier
Enoximone（III型选择性磷酸二酯酶抑制剂）和多巴酚丁胺（β受体激动剂）是冠状动脉旁路手术术后管理中常用的正性肌力药物。本研究的目的是表征它们对人乳内动脉（IMA）和胃网膜动脉（GEA）的舒张作用，并检验它们的组合可能具有大于相加的舒张作用的假设。在器官浴中，在用U46619（血栓烷A2模拟物）、去甲肾上腺素（NE）或KCl预收缩的IMA（n = 86）环上测试依诺昔酮和多巴酚丁胺的舒张作用。用U46619和NE预收缩GEA（n = 42），观察多巴酚丁胺和依诺昔酮对GEA环的舒张作用。用U46619或NE预收缩IMA（n = 24）环，观察依诺昔酮和多巴酚丁胺合用的作用。在罂粟碱（10（-4）M）引起的最大舒张作用中，依诺昔酮（≤ 10（-3）M）引起NE、U46619或KCl预收缩的IMA完全舒张。多巴酚丁胺（≥ 10（-3）M）可使NE或KCl预收缩的IMA完全舒张，但对U46619预收缩的环仅舒张46%（95%CI，27-65）。在GEA环中观察到类似的松弛模式，多巴酚丁胺在用U46619预收缩的GEA中诱导部分松弛。在用U46619预收缩的节段中，烯诺昔酮和多巴酚丁胺的pD 2值均显着较低。体外阈值松弛剂浓度在治疗血浆浓度的上限或范围内。在与U46619或NE收缩的IMA中，组合的舒张效应比理论相加效应显著更重要。依诺昔酮和多巴酚丁胺是有效的体外血管扩张剂，但在治疗范围内的浓度下，在IMA和GEA中发挥弱的舒张作用。然而，该组合的血管舒张作用大于相加作用，表明除了相加性肌力作用之外，该组合的血管舒张作用可能对接受冠状动脉旁路移植术的患者有益。
Enoximone (a type III-selective phosphodiesterase inhibitor) and dobutamine (a beta-receptor agonist) are positive inotropic drugs frequently used in the postoperative management of coronary bypass surgery. The purpose of this study was to characterize their relaxant effects on the human internal mammary artery (IMA) and the gastroepiploic artery (GEA) and to test the hypothesis that their combination may have greater than additive relaxant effects. In organ baths, the relaxant effects of enoximone and dobutamine were tested on rings of IMA (n = 86) precontracted with U46619 (a thromboxane A2 mimetic), norepinephrine (NE), or KCl. The relaxant effects of dobutamine and enoximone also were tested on rings of GEA (n = 42) precontracted with U46619 and NE. The effect of the combination of enoximone and dobutamine were tested on rings of IMA (n = 24) precontracted with U46619 or NE. With respect to maximal relaxations induced by papaverine (10(-4) M), enoximone (< or =10(-3) M) caused full relaxations of IMA precontracted with NE, U46619, or KCI. Dobutamine (< or =10(-3) M) caused full relaxations of IMA precontracted with NE or KCI but only 46% (95% CI, 27-65) relaxation in the rings precontracted with U46619. Similar patterns of relaxation were observed in GEA rings, with dobutamine inducing partial relaxation in GEA precontracted with U46619. The pD2 values of enoximone and dobutamine were both significantly lower in segments precontracted with U46619. The in vitro threshold relaxant concentrations were in the upper limits or over the range of therapeutic plasma concentrations. The relaxant effect of the combination was significantly more important than the theoretic additive effect in IMA contracted with U46619 or NE. Enoximone and dobutamine are potent in vitro vasodilators but exert weak relaxant effects in IMA and GEA at concentrations in the therapeutic range. There is, however, a greater than additive vasorelaxant effect of the combination, suggesting that the vasorelaxant effect of the combination, in addition to the additive inotropic effect, may be beneficial to patients undergoing coronary bypass grafting.
正性肌力药物和血管扩张剂治疗对充血性心肌病患者舒张特性的不同影响。
影响因子：
37.8
作者：
Carroll,JD;Lang,RM;Neumann,AL;Borow,KM;Rajfer,SI
通讯作者：
Rajfer,SI